Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
12.02
+0.71 (6.28%)
At close: May 12, 2025, 4:00 PM
12.02
0.00 (0.00%)
After-hours: May 12, 2025, 6:37 PM EDT
Zymeworks Revenue
Zymeworks had revenue of $27.11M in the quarter ending March 31, 2025, with 170.29% growth. This brings the company's revenue in the last twelve months to $93.38M, up 85.05% year-over-year. In the year 2024, Zymeworks had annual revenue of $76.30M with 0.38% growth.
Revenue (ttm)
$93.38M
Revenue Growth
+85.05%
P/S Ratio
9.73
Revenue / Employee
$326,517
Employees
286
Market Cap
837.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ZYME News
- 4 days ago - Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 14 days ago - Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline - Seeking Alpha
- 14 days ago - Zymeworks: Poised For Growth With Platform Validation - Seeking Alpha
- 17 days ago - Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting - GlobeNewsWire
- 21 days ago - Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development - GlobeNewsWire
- 25 days ago - Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewsWire
- 6 weeks ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire